抗原
交叉展示
细胞毒性T细胞
CTL公司*
佐剂
T细胞
肿瘤抗原
树突状细胞
生物
表位
癌症免疫疗法
免疫系统
免疫疗法
CD8型
抗原提呈细胞
免疫学
癌症研究
MHC I级
生物化学
体外
作者
Bijun Zeng,Anton P. J. Middelberg,Adrian Tandhyka Gemiarto,Kelli P. A. MacDonald,Alan G. Baxter,Meghna Talekar,Davide Moi,Kirsteen M. Tullett,Irina Caminschi,Mireille H. Lahoud,Roberta Mazzieri,Riccardo Dolcetti,Ranjeny Thomas
摘要
Non–antigen-specific stimulatory cancer immunotherapies are commonly complicated by off-target effects. Antigen-specific immunotherapy, combining viral tumor antigen or personalized neoepitopes with immune targeting, offers a solution. However, the lack of flexible systems targeting tumor antigens to cross-presenting dendritic cells (DCs) limits clinical development. Although antigen–anti-Clec9A mAb conjugates target cross-presenting DCs, adjuvant must be codelivered for cytotoxic T lymphocyte (CTL) induction. We functionalized tailored nanoemulsions encapsulating tumor antigens to target Clec9A (Clec9A-TNE). Clec9A-TNE encapsulating OVA antigen targeted and activated cross-presenting DCs without additional adjuvant, promoting antigen-specific CD4+ and CD8+ T cell proliferation and CTL and antibody responses. OVA-Clec9A-TNE–induced DC activation required CD4 and CD8 epitopes, CD40, and IFN-α. Clec9A-TNE encapsulating HPV E6/E7 significantly suppressed HPV-associated tumor growth, while E6/E7–CpG did not. Clec9A-TNE loaded with pooled B16-F10 melanoma neoepitopes induced epitope-specific CD4+ and CD8+ T cell responses, permitting selection of immunogenic neoepitopes. Clec9A-TNE encapsulating 6 neoepitopes significantly suppressed B16-F10 melanoma growth in a CD4+ T cell–dependent manner. Thus, cross-presenting DCs targeted with antigen–Clec9A-TNE stimulate therapeutically effective tumor-specific immunity, dependent on T cell help.
科研通智能强力驱动
Strongly Powered by AbleSci AI